Pfizer's inotuzumab ozogamicin gets Priority Review for ALL

Pfizer Inc. (NYSE:PFE) said FDA accepted and granted Priority Review to a BLA for inotuzumab ozogamicin to treat relapsed or refractory B cell precursor acute lymphoblastic leukemia. Its PDUFA date is August.

An MAA for inotuzumab ozogamicin is under EMA review in the indication...